ArticleOphthalmology and therapy2021
Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States.
Article in Ophthalmology and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Bayesian network analysis of drug treatment strategies for thyroid associated ophthalmopathy.International ophthalmology · 2024Pooled it
- A meta-analysis of the efficacy of two-wall orbital decompression operations for thyroid-associated ophthalmopathy.International ophthalmology · 2024Pooled it
- Efficacy and Safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves'ophthalmopathy: a systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.The Journal of clinical endocrinology and metabolism · 2023Trial
- Post Hoc MRI Analysis of Orbital Soft Tissue Volumes Pre- and Post-Teprotumumab in Patients with Chronic, Low-Activity Thyroid Eye Disease.Ophthalmology and therapy · 2026Article
- Association of smoking with thyroid eye disease and related diplopia in a Japanese population: a retrospective study.Japanese journal of ophthalmology · 2026Article
- Impacts of Thyroid Eye Disease (TED), Beyond the Signs and Symptoms: Results from the ElevaTED Patient Survey.Ophthalmology and therapy · 2026Article
- Quality of life and psychosocial well-being in thyroid eye disease in Japan: pre-teprotumumab national survey.Journal of the Endocrine Society · 2026Article
- ProptoView: AI-based digital exophthalmometry using multi-view facial images in a multinational validation study.Journal of translational medicine · 2026Article
- Approach to the patient: therapeutic mitigation of lacrimal manifestations in thyroid eye disease.The Journal of clinical endocrinology and metabolism · 2026Review
- Light Discomfort Thresholds in Patients with Moderate-to-Severe Active versus Mild Non-Active Thyroid Eye Disease.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Aberrant brain functional connectivity in patients with dysthyroid optic neuropathy: a resting-state fMRI study.Frontiers in neuroscience · 2026Article
- Higher serum IgG4 levels correlate with better quality of life in mild Graves' orbitopathy: a preliminary report.Endocrine connections · 2026Article
- Orbital asymmetry degree: a potentialFrontiers in endocrinology · 2026Article
- Stigma and Its Influencing Factors Among Chinese Patients with Thyroid-Associated Ophthalmopathy: A Cross-Sectional Study.Patient preference and adherence · 2026Article
- Process to radioactive iodine treatment for Graves' hyperthyroidism: condemned or absolved?Journal of endocrinological investigation · 2025Review
- Quality and content evaluation of thyroid eye disease treatment information on TikTok and Bilibili.Scientific reports · 2025Article
- The Use of Biologics for Thyroid Eye Disease.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Sleep quality and its determinants in patients with thyroid eye disease: a cross-sectional study.European journal of medical research · 2025Article
- Teprotumumab Improves Quality of Life in Thyroid Eye Disease: Meta-analysis and Matching-adjusted Indirect Comparison.Journal of the Endocrine Society · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThyroid eye disease (TED) is an autoimmune condition producing ocular pain, dysmotility, and ocular structure and function changes. As disease activity changes, redness, swelling, and pain can improve, but eye comfort, appearance, and motility alterations often persist. There are limited data on chronic TED patient-reported outcomes. This study examined chronic US TED patient-reported symptoms and quality of life (QOL).
methodsExisting data from an online survey regarding chronic TED signs/symptoms and patient QOL were retrospectively examined. The Graves' Ophthalmopathy QOL instrument (GO-QOL; 0-100, 100 = highest QOL) evaluated overall, appearance, and vision-related QOL. Influencing factors were examined by stratifying patients into low (overall QOL ≤ 50), moderate (> 50 and < 75), and high (≥ 75) QOL categories.
resultsOne hundred patients (47 women, 81 Caucasian, 45.2 ± 7.6 years) were included. The duration of inactive TED was 3.0 ± 4.6 years and total duration of TED was 5.8 ± 5.9 years. Patients reported an average of 20 doctor visits/year and high prevalence of anxiety (34%) and depression (28%). Prior TED treatments for the polled population included systemic corticosteroids during active TED (25%), orbital radiation (5%), and surgery (25%). The overall GO-QOL score was 60.5 ± 21.8 (vision-related: 58.6 ± 24.0, appearance-related: 62.3 ± 25.1). Patients with low QOL more frequently reported hypothyroidism, anxiety, and a larger number of chronic TED signs/symptoms (average: 4.2). Compared to high QOL patients, low QOL patients had more pain (39% vs. 13%), blurry vision (30% vs. 17%), and diplopia (27% vs. 3%, all p ≤ 0.025). Additionally, the low QOL group more often had TED-specific surgical history (45% vs. 10%, p = 0.002), more often reported disability/unemployment (21% vs. 3%, p = 0.055), and had a higher number of doctor visits (40 vs. 5 visits/person/year, p < 0.001).
conclusionTED severely impacts patient QOL, despite becoming stable and chronic. Patients reported vision and appearance impairment and psychosocial impact long after acute TED had subsided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.